SCHEMBL3560133

SCHEMBL3560133

COc1ccccc1-c1cn(S(=O)(=O)c2ccc(C)cc2)c2ncc(-c3ccc(N)c(C(=O)OC(=O)C(F)(F)F)c3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 3/20 0.43
MAP4K1 Q92918 2/20 0.42
KMT2A Q03164 6/20 0.41
MAPT P10636 5/20 0.41
ALDH1A1 P00352 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 2/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
RECQL P46063 1/20 0.35
SLC1A3 P43003 2/20 0.35
SLC1A2 P43004 2/20 0.35
SLC1A1 P43005 2/20 0.35
PIM1 P11309 1/20 0.34
PIM2 Q9P1W9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3560130 0.90 PTPN11 (0.47) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL3561085 0.89 PTPN11 (0.44) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL13342637 0.88 PTPN11 (0.51) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL3565148 0.86 MAP4K1 (0.59) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL3564256 0.83 PTPN11 (0.43) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL13368497 0.82 MAPT (0.47) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL1516627 0.82 PTPN11 (0.47) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL3414082 0.82 TSHR (0.46) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL3568791 0.80 PTPN11 (0.47) PTPN11MAP4K1KMT2AMAPTALDH1A1
SCHEMBL3565147 0.79 MAP4K1 (0.48) PTPN11MAP4K1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
EP-2134343-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS MAP4K2, PDXK, MAP4K1 PTPN11 1303/4885MAP4K1 3/4885KMT2A 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.